FWIW my guess is that some still put lot of value on the Teva trial outcome. 

 

The final trail brief have been submitted and most folk only know realize that odds are much in Corcept's favor.  Trials outcomes always are uncertain, so some think that Teva/ Corcept might settle right before.

 

In any case since many invest based on current revenue (and discount all the pipeline to add little) removal of uncertainty should Corcept settle or win at trial will IMHO create a bump in the market's perceived value.  Hence stock is acting like a Biotech run-up into PDUFA date...